SGLT2 inhibition reduces myocardial oxygen consumption.

SGLT2 inhibition is associated with a reduced risk of cardiac disease that is still largely unexplained. According to one hypothesis, improved myocardial energetics may explain the cardioprotective effects of SGLT2i. However, recent mechanistic studies that have addressed this question have lacked the power to detect discrete but still clinically significant effects. We pooled data from two recent randomized clinical trials and performed a meta-analysis to determine the effect of SGLT2 inhibition on myocardial oxygen consumption and myocardial external efficiency measured by positron emission tomography. SGLT2 inhibition reduced myocardial oxygen consumption (-1.06 [95%CI: 0.22-1.89] mL/100 g/min (n = 59, p = 0.01)), but did not affect myocardial external efficiency (2.22 [95%CI: 0.66-5.11] % (n = 59, p = 0.13)). /interpretation: SGLT2 inhibition reduces myocardial oxygen consumption at rest, which may contribute to the drugs' cardioprotective effects.

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

JO reports fees to his institution from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Portola, Pfizer, Roche Diagnostics and Sanofi. AÅ has received speaker's fees and participated in Advisory Board meetings with AstraZeneca. PN reports fees to her institution from AstraZeneca and Glaxo Smith Kline PLCES. ES, ESL, KML and LCG have no financial disclosures.